Actively Recruiting
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
Led by University Of Perugia · Updated on 2024-08-09
190
Participants Needed
1
Research Sites
89 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Systemic autoimmune and chronic inflammatory diseases are a group of chronic illnesses whose treatment is usually very prolonged, often lifelong, and is essential to keep the disease under control, thus reducing the risk of complications and allowing the best possible quality of life for patients. The drugs used for treating these diseases are mostly immunosuppressants, which reduce the activity of the immune system, whose alteration is responsible for the disease. Although all available drugs are effective for treating these diseases, for reasons largely unknown, each drug is effective only in a percentage of patients. As a result, it is often necessary to try several different treatments before identifying an effective one for the individual patient. The therapeutic effects are often slow, and it is therefore necessary to take a treatment for weeks or months before its effectiveness can be determined. The initial period is also when side effects most often appear. The aim of this study is to evaluate whether the addition of remote monitoring visits and other patient support services to traditional periodic medical visits in the first months after the introduction of a new treatment leads to an improvement in adherence, response, and quality of life for the patient.
CONDITIONS
Official Title
Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Rheumatoid Arthritis, Psoriatic Arthritis, Spondyloarthritis, Ankylosing Spondylitis, Systemic Sclerosis, Systemic Lupus Erythematosus, or Sjogren's Disease
- Prescribed a new immunosuppressive medication from the following: Methotrexate, Sulfasalazine, Leflunomide, Mycophenolate Mofetil, Azathioprine, Cyclosporine A, Tacrolimus, TNF inhibitors (etanercept, adalimumab, golimumab, certolizumab pegol), IL6 inhibitors (tocilizumab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (ustekinumab, guselkumab, risankizumab), JAK-inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib), Belimumab, or Anifrolumab
You will not qualify if you...
- Treatment with a medication not approved for the condition
- Inability to use a device for remote calls, even with caregiver assistance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rheumatology Unit - Perugia Univeristy Hospital
Perugia, PG, Italy, 06129
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here